Thus, MGMT hypermethylation, and its consequent loss of expression, could be a prognostic biomarker for HNSCC patients candidates for cisplatin chemotherapy, predicting the chances of drug resistance. The gene discussed is MGMT; the disease is head and neck squamous cell carcinoma.